Cerebrolysin is unlike typical peptide drugs—it's not a single molecule but a complex mixture of low-molecular-weight neuropeptides and amino acids derived from purified pig brain proteins. This enzymatically processed preparation contains fragments that mimic the activity of natural neurotrophic factors like BDNF, GDNF, and NGF, without requiring the complex protein structures of the full factors. The mixture crosses the blood-brain barrier and appears to promote neuronal survival, stimulate neuroplasticity, enhance synapse formation, and protect against excitotoxicity. Developed in Austria and approved in over 50 countries (notably not the US or UK), Cerebrolysin has been used clinically since the 1970s for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia. The CASTA and CARS trials in stroke patients showed improved cognitive outcomes. Controversy exists: some Western neurologists dismiss it as insufficiently characterized, while clinicians in Europe, Asia, and Russia consider it a valuable tool. It represents an older, empirical approach to neuropharmacology that predates the era of single-target drug design.
verifiedRecommended Supplier
Get Cerebrolysin
Sourced from Ascension Peptides. Verified ≥Pharmaceutical grade (standardized to biological activity) purity, third-party tested. COA included.
Cerebrolysin is unlike typical peptide drugs—it's not a single molecule but a complex mixture of low-molecular-weight neuropeptides and amino acids derived from purified pig brain proteins. This enzymatically processed preparation contains fragments that mimic the activity of natural neurotrophic factors like BDNF, GDNF, and NGF, without requiring the complex protein structures of the full factors. The mixture crosses the blood-brain barrier and appears to promote neuronal survival, stimulate neuroplasticity, enhance synapse formation, and protect against excitotoxicity. Developed in Austria and approved in over 50 countries (notably not the US or UK), Cerebrolysin has been used clinically since the 1970s for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia. The CASTA and CARS trials in stroke patients showed improved cognitive outcomes. Controversy exists: some Western neurologists dismiss it as insufficiently characterized, while clinicians in Europe, Asia, and Russia consider it a valuable tool. It represents an older, empirical approach to neuropharmacology that predates the era of single-target drug design.
Research Benefits
check_circle
Neurotrophic effects mimicking BDNF/NGF
check_circle
May improve recovery after stroke
check_circle
Supports neuroplasticity and synapse formation
check_circle
Potential cognitive benefits in dementia
check_circle
Neuroprotective against various insults
check_circle
Long clinical track record in many countries
check_circle
Crosses blood-brain barrier
check_circle
May enhance memory and learning
Research Applications
science
Stroke recovery
Active research area with published studies
science
Traumatic brain injury (TBI)
Active research area with published studies
science
Alzheimer's disease
Active research area with published studies
science
Vascular dementia
Active research area with published studies
science
Parkinson's disease
Active research area with published studies
science
Pediatric neurodevelopmental disorders
Active research area with published studies
science
Cognitive enhancement
Active research area with published studies
science
Post-surgical cognitive dysfunction
Active research area with published studies
Frequently Asked Questions
Scientific References
1
Cerebrolysin in Vascular Dementia: A Systematic Review